Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDUVCZ)

Drug Name

IPH-2101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting MHC class I NK cell receptor 2DL3 (CD158b2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2102	DMPBR0D	Acute myeloid leukaemia	2A60	Phase 2	[2]
mab 1-7F9	DMQOBH4	Multiple myeloma	2A83	Phase 2	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting MHC class I NK cell receptor 2DL2 (CD158b1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2102	DMPBR0D	Acute myeloid leukaemia	2A60	Phase 2	[2]
mab 1-7F9	DMQOBH4	Multiple myeloma	2A83	Phase 2	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting MHC class I NK cell receptor 2DL1 (CD158A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2102	DMPBR0D	Acute myeloid leukaemia	2A60	Phase 2	[2]
mab 1-7F9	DMQOBH4	Multiple myeloma	2A83	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MHC class I NK cell receptor 2DL1 (CD158A)	TT4UXPE	KI2L1_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DL2 (CD158b1)	TTU0P73	KI2L2_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DL3 (CD158b2)	TTEX3SI	KI2L3_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DS1 (CD158h)	TTVWAGF	KI2S1_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DS2 (CD158j)	TTV3CFI	KI2S2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01222286) Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma. U.S. National Institutes of Health.
2	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
3	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.